PT  - JOURNAL ARTICLE
AU  - Chapman, Kenneth R.
AU  - Van Zyl-Smit, Richard N
AU  - Kerstjens, Huib A M
AU  - Maspero, Jorge F
AU  - Hosoe, Motoi
AU  - Tanase, Ana-Maria
AU  - Pethe, Abhijit
AU  - D’Andrea, Peter
AU  - Brittain, Dominic
TI  - Evaluating contributions of mometasone (MF), indacaterol (IND) and glycopyrronium (GLY) to reduction of exacerbations in patients with inadequately controlled asthma: Results from the IRIDIUM study
AID  - 10.1183/13993003.congress-2021.OA1489
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - OA1489
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/OA1489.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/OA1489.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Background: In IRIDIUM study, high-dose MF/IND/GLY once-daily showed substantial reduction in exacerbations vs high-dose fluticasone/salmeterol (FLU/SAL) twice daily. We evaluated contributions of MF, IND and GLY to exacerbation reduction in pts with inadequately controlled asthmaMethods: IRIDIUM (NCT02571777) was a 52-wk, randomised, double-blind study in symptomatic pts (ACQ-7≥1.5), with ≥1 exacerbation in previous year, % predicted FEV1 <80%. Reductions in annualised rate of moderate/severe, severe, and all (mild, moderate and severe) exacerbations with pooled high-dose MF/IND/GLY (160/150/50 μg) and medium-dose (80/150/50 μg) vs pooled high-dose MF/IND (320/150 μg) and medium-dose (160/150 μg) were evaluated for more precise estimation of contribution of GLY. Corresponding comparisons of high-dose MF/IND vs high-dose FLU/SAL (500/50 μg) were evaluated to estimate contribution of MF and INDResult: High-dose MF/IND/GLY showed clinically meaningful reductions in moderate/severe (36%), severe (42%) and all exacerbations (40%) vs high-dose FLU/SAL. Pooled MF/IND/GLY showed reduction in moderate/severe (14%), severe (15%) and all exacerbations (17%) vs pooled MF/IND, highlighting potential role of GLY in exacerbation reduction. High-dose MF/IND showed reductions in moderate/severe (25%), severe (27%) and all exacerbations (25%) vs high-dose FLU/SAL, showing benefits of MF and INDConclusion: Data analysis evaluated in context of 36-42% reduction observed with high-dose MF/IND/GLY vs FLU/SAL in IRIDIUM study highlight considerable contributions of GLY, IND and MF to exacerbation reductionFootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA1489.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).